A long-term assessment of flurbiprofen.
A multi-centre open study of flurbiprofen was started in 1971 to provide regular clinical and laboratory data on patients with a variety of arthritic conditions. To date, 1220 patients have received the drug in a dosage varying from 75 mg to 400 mg daily. Flurbiprofen has been shown to be effective in relieving symptoms in the degenerative and inflammatory arthritides and side-effects have not proved a problem. Patients aged 65 years and over appear to tolerate the drug as well as their younger counterparts, an important finding in a group of patients notoriously intolerant of many drugs.
D001168:Arthritis / Q000188:drug therapy*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001847:Bone Diseases / Q000188:drug therapy*; D005260:Female; D005480:Flurbiprofen / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007592:Joint Diseases / Q000188:drug therapy*; D008297:Male; D010003:Osteoarthritis / Q000188:drug therapy; D010166:Palliative Care; D011422:Propionates / Q000627:therapeutic use*; D013997:Time Factors
D011422:Propionates; D005480:Flurbiprofen